ATR
AptarGroup, Inc.
ATR's fundamentals are mixed: revenue grew 9%, but earnings per share fell 34%. At 34x earnings, it's trading in line with its usual 32x. Its downside scenario is about four times its upside.
ATR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
ATR's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
ATR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $142 | — |
| Cheap | 24x | $100 | -29% |
| Fair | 32x | $131 | -7.7% |
| Current | 34x | $142 | — |
| Expensive | 35x | $145 | +2.1% |
Historical ranges are pointers, not guarantees.
ATR's PE is in its expensive range at 34x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its cheap range.
ATR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ATR, with profitability improving.
ATR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.08 | +48% |
| Q3 2026 | $4.12 | -34% |
| Q2 2026 | $5.53 | -4.7% |
| Q1 2026 | $5.84 | +6.8% |
| Q4 2025 | $5.89 | +6.5% |
| Q3 2025 | $6.24 | +25% |
| Q2 2025 | $5.80 | +22% |
| Q1 2025 | $5.47 | +17% |
| Q4 2024 | $5.53 | +30% |
ATR's earnings per share have fallen from their peak: $4.12 over the past year, against $6.24 in late 2025.
ATR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +6% |
| Q2 2026 | $1B | +6.3% |
| Q1 2026 | $982.9M | +11% |
| Q4 2025 | $962.7M | +14% |
| Q3 2025 | $961.1M | +5.7% |
| Q2 2025 | $966M | +6.1% |
| Q1 2025 | $887.3M | -3.1% |
| Q4 2024 | $848.1M | +1.1% |
ATR's revenue has grown year over year for six quarters in a row: $1B last quarter, up 6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1 points |
| Q2 2026 | 12% | -2.6 points |
| Q1 2026 | 11% | -1.8 points |
| Q4 2025 | 11% | -3.1 points |
| Q3 2025 | 14% | -1 points |
| Q2 2025 | 15% | +1.1 points |
| Q1 2025 | 13% | +0.5 points |
| Q4 2024 | 14% | +4.1 points |
ATR's operating margin was 13% last quarter, down 1 points from the same quarter a year ago.
ATR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $98.6M | -14% |
| Q2 2026 | $45.9M | -27% |
| Q1 2026 | $53.3M | +106% |
| Q4 2025 | $96.9M | -14% |
| Q3 2025 | $114.3M | -30% |
| Q2 2025 | $62.5M | -17% |
| Q1 2025 | $25.9M | +55% |
| Q4 2024 | $112.2M | -19% |
ATR's free cash flow has been positive every quarter for seven years: $295M over the past year, down 6.4% from the year before.
ATR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -61K shares |
| 1 year | -3.7% | -2.5M shares |
| 3 years | -4.3% | -2.9M shares |
| 5 years | -5.4% | -3.7M shares |
| Available history | -3.1% | -2M shares |
ATR has 64M diluted shares, down 3.7% from a year ago, with $355M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $30M |
| Q2 2026 | $50M |
| Q1 2026 | $100M |
| Q4 2025 | $175M |
| Q3 2025 | $40M |
| Q2 2025 | $70M |
| Q1 2025 | $80M |
| Q4 2024 | $37.3M |
ATR spent $355M buying back its own shares over the past year, up 56% from the year before.
ATR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
ATR's net debt is about 1.5 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
ATR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 78.5 | Neutral |
ATR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
ATR PE vs Healthcare Sector
| Metric | ATR | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 33% above |
| PE % | 80 | 29 | 51 pts above |
ATR is trading at 34x earnings, a 33% premium to the Healthcare sector's median of 26x.
ATR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 9.4% above |
| 20 week MA | $130.0 | 9% above |
| 50 week MA | $127.1 | 11% above |
| 100 week MA | $135.9 | 4.3% above |
| 200 week MA | $135.3 | 4.8% above |
ATR is in an uptrend: it's above all five of its weekly moving averages, and 4.8% above its 200-week average.
ATR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.0 | $135.7 | +18% |
| 2021 | $135.7 | $116.3 | -14% |
| 2022 | $116.3 | $110.0 | -5.4% |
| 2023 | $110.0 | $123.6 | +12% |
| 2024 | $123.6 | $158.2 | +28% |
| 2025 | $158.2 | $123.3 | -22% |
| 2026 YTD | $123.3 | $141.7 | +15% |
ATR has finished lower in three of the last six years. It's up 15% so far in 2026.